Developer docs
API playgroundTry for free, no card

Search company profiles

Gyroscope Therapeutics

Full company profile

uuid0002awn

Namestring
Gyroscope Therapeutics
Legal namestring
Gyroscope Therapeutics
Websiteurl
gyroscopetx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company founded in 2016 and headquartered in Stevenage. The company is focused exclusively on developing gene therapies for diseases of the eye, with its lead investigational candidate GT005 being evaluated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD), a leading cause of vision loss in adults over 50. Its scientific foundation is rooted in academic founders from the University of Southampton and Newcastle, and the company expanded its delivery capability in 2019 by acquiring Orbit Biomedical, which specializes in subretinal surgical delivery technology relevant to ocular gene therapies.

The company's core technology platform combines a gene therapy directed at the complement pathway underlying GA with a proprietary surgical delivery system, positioning it as a potential one-time, disease-modifying treatment for an indication with no approved therapies. GT005 is the only product disclosed in the input data, and it remains under clinical evaluation with no commercialized product. The business is pre-revenue: the company does not yet have pricing, distribution, or marketing channels because it has not reached commercialization.

Gyroscope has financed its clinical development through venture capital, securing cumulative disclosed funding of roughly $269.5 million across rounds from Syncona Partners, Cambridge Innovation Capital, Sofinnova Investments, Forbion Capital Partners, Fosun Pharma, Tetragon, T. Rowe Price, and Sanofi. Sanofi's November 2021 equity investment of up to $60 million signals strategic-pharma interest and supports continued clinical advancement of GT005. With 51–100 employees and operations centered in the UK, the company remains a focused, single-indication developer with an integrated asset-plus-delivery platform.

Short descriptiontext

Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company developing ocular treatments, with lead candidate GT005 in clinical evaluation for geographic atrophy secondary to dry age-related macular degeneration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
gene therapy, ophthalmic therapeutics, retinal disease treatment, age-related macular degeneration, geographic atrophy therapy
Industry2 codes
1Rare Ophthalmology Disorder Therapies
CodeHLAIAIAKPrimaryYes
2Ophthalmology Specialty Pharmaceuticals
CodeHLAIACAKPrimaryNo
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
Product category
Ophthalmic Gene Therapy
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye. Its lead investigational product, GT005, is being evaluated as a one-time gene therapy for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), an advanced form of the disease that causes progressive vision loss in adults over 50.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gyroscope Therapeutics is a UK-based gene therapy company focused on developing treatments for eye diseases. The company's lead product is GT005, an investigational gene therapy being evaluated for geographic atrophy associated with age-related macular degeneration.

Product and service1 record
1GT005
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Adverum Biotechnologies
TypeDirect peer
Description

Clinical-stage gene therapy company developing ADVM-022 (intravitreal gene therapy) for wet AMD and other ocular diseases. Directly comparable to Gyroscope as a fellow ocular gene-therapy developer with a single-asset, clinical-stage profile.

2REGENXBIO
TypeDirect peer
Description

Gene therapy company with an ophthalmology pipeline including RGX-314 for wet AMD (partnered with AbbVie). Closely comparable to Gyroscope as a clinical-to-commercial-stage ocular gene-therapy developer with AAV-based delivery.

3MeiraGTx
TypeDirect peer
Description

Clinical-stage gene therapy company with a dedicated ophthalmology pillar (including AAV-based programs for retinal diseases) and in-house manufacturing. Directly comparable to Gyroscope in platform, modality, and clinical-stage ocular focus.

4Nanoscope Therapeutics
TypeDirect peer
Description

Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including GA and Stargardt disease. Closely comparable to Gyroscope as a retinal gene-therapy developer pursuing GA and dry AMD.

54D Molecular Therapeutics
TypeDirect peer
Description

Clinical-stage gene therapy company with ophthalmology programs including 4D-150 for wet AMD. Comparable to Gyroscope as an AAV-based ocular gene-therapy developer advancing through clinical trials with platform leverage.

6Applied Genetic Technologies Corp (AGTC)
TypeEmerging player
Description

Clinical-stage gene therapy developer focused on rare inherited retinal diseases using AAV vectors. Comparable to Gyroscope in modality (ocular AAV gene therapy) and clinical-stage focus, with a more inherited-retinal-disease emphasis.

7Spark Therapeutics (Roche)
TypeBroad incumbent
Description

Pioneer in ocular gene therapy (Luxturna) now part of Roche. Comparable to Gyroscope as a leader in ophthalmic gene therapy with proven AAV platform, regulatory, and commercial infrastructure that Gyroscope would need to build.

8Apellis Pharmaceuticals
TypeDirect peer
Description

Commercial-stage biotech with pegcetacoplan (Syfovre), the first FDA-approved treatment for geographic atrophy. Directly comparable as a GA-focused therapeutic competitor whose commercial launch defines the market GT005 would enter.

9Iveric Bio (Astellas)
TypeDirect peer
Description

Developer of avacincaptad pegol (Izervay), an approved complement inhibitor for GA, acquired by Astellas. Directly comparable to Gyroscope as a GA-focused therapeutic competitor and a recent example of large-pharma M&A in the GA space.

10Novartis
TypeOthers
Description

Large incumbent pharmaceutical company with a meaningful ophthalmology franchise (including Lucentis and Beovu) and a gene-therapy capability via AveXis/Zolgensma. Comparable as both a potential acquirer/partner and a benchmark for what commercial-scale ophthalmology infrastructure looks like.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gyroscope Therapeutics

Ophthalmic Gene Therapygyroscopetx.com

Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company developing ocular treatments, with lead candidate GT005 in clinical evaluation for geographic atrophy secondary to dry age-related macular degeneration.

What Gyroscope Therapeutics does

Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company founded in 2016 and headquartered in Stevenage. The company is focused exclusively on developing gene therapies for diseases of the eye, with its lead investigational candidate GT005 being evaluated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD), a leading cause of vision loss in adults over 50. Its scientific foundation is rooted in academic founders from the University of Southampton and Newcastle, and the company expanded its delivery capability in 2019 by acquiring Orbit Biomedical, which specializes in subretinal surgical delivery technology relevant to ocular gene therapies.

The company's core technology platform combines a gene therapy directed at the complement pathway underlying GA with a proprietary surgical delivery system, positioning it as a potential one-time, disease-modifying treatment for an indication with no approved therapies. GT005 is the only product disclosed in the input data, and it remains under clinical evaluation with no commercialized product. The business is pre-revenue: the company does not yet have pricing, distribution, or marketing channels because it has not reached commercialization.

Gyroscope has financed its clinical development through venture capital, securing cumulative disclosed funding of roughly $269.5 million across rounds from Syncona Partners, Cambridge Innovation Capital, Sofinnova Investments, Forbion Capital Partners, Fosun Pharma, Tetragon, T. Rowe Price, and Sanofi. Sanofi's November 2021 equity investment of up to $60 million signals strategic-pharma interest and supports continued clinical advancement of GT005. With 51–100 employees and operations centered in the UK, the company remains a focused, single-indication developer with an integrated asset-plus-delivery platform.

Gyroscope Therapeutics firmographics

Firmographics
Name
Gyroscope Therapeutics
Legal name
Gyroscope Therapeutics
Website
https://gyroscopetx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company developing ocular treatments, with lead candidate GT005 in clinical evaluation for geographic atrophy secondary to dry age-related macular degeneration.
Ownership category
akta.pro rank

Gyroscope Therapeutics industry classification

Industry
Product category
Ophthalmic Gene Therapy
NAICS
Ophthalmic Goods Manufacturing (339115)
akta.pro primary industry
Rare Ophthalmology Disorder Therapies (HLAIAIAK)
akta.pro secondary industry
Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

  • Gene therapy
  • Ophthalmic therapeutics
  • Retinal disease treatment
  • Age-related macular degeneration
  • Geographic atrophy therapy

Where Gyroscope Therapeutics is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Markets served

Gyroscope Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Gyroscope Therapeutics product offering

Product offering

Core offering

Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye. Its lead investigational product, GT005, is being evaluated as a one-time gene therapy for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), an advanced form of the disease that causes progressive vision loss in adults over 50.

Product overview

Gyroscope Therapeutics is a UK-based gene therapy company focused on developing treatments for eye diseases. The company's lead product is GT005, an investigational gene therapy being evaluated for geographic atrophy associated with age-related macular degeneration.

Differentiator

Problem solved

Functional benefit

Products and services

  • GT005

Companies that use Gyroscope Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Gyroscope Therapeutics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Gyroscope Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Gyroscope Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (intravitreal gene therapy) for wet AMD and other ocular diseases. Directly comparable to Gyroscope as a fellow ocular gene-therapy developer with a single-asset, clinical-stage profile.
  • REGENXBIO: Gene therapy company with an ophthalmology pipeline including RGX-314 for wet AMD (partnered with AbbVie). Closely comparable to Gyroscope as a clinical-to-commercial-stage ocular gene-therapy developer with AAV-based delivery.
  • MeiraGTx: Clinical-stage gene therapy company with a dedicated ophthalmology pillar (including AAV-based programs for retinal diseases) and in-house manufacturing. Directly comparable to Gyroscope in platform, modality, and clinical-stage ocular focus.
  • Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including GA and Stargardt disease. Closely comparable to Gyroscope as a retinal gene-therapy developer pursuing GA and dry AMD.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with ophthalmology programs including 4D-150 for wet AMD. Comparable to Gyroscope as an AAV-based ocular gene-therapy developer advancing through clinical trials with platform leverage.
  • Apellis Pharmaceuticals: Commercial-stage biotech with pegcetacoplan (Syfovre), the first FDA-approved treatment for geographic atrophy. Directly comparable as a GA-focused therapeutic competitor whose commercial launch defines the market GT005 would enter.
  • Iveric Bio (Astellas): Developer of avacincaptad pegol (Izervay), an approved complement inhibitor for GA, acquired by Astellas. Directly comparable to Gyroscope as a GA-focused therapeutic competitor and a recent example of large-pharma M&A in the GA space.

Emerging players

  • Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy developer focused on rare inherited retinal diseases using AAV vectors. Comparable to Gyroscope in modality (ocular AAV gene therapy) and clinical-stage focus, with a more inherited-retinal-disease emphasis.

Broad incumbents

  • Spark Therapeutics (Roche): Pioneer in ocular gene therapy (Luxturna) now part of Roche. Comparable to Gyroscope as a leader in ophthalmic gene therapy with proven AAV platform, regulatory, and commercial infrastructure that Gyroscope would need to build.

Others

  • Novartis: Large incumbent pharmaceutical company with a meaningful ophthalmology franchise (including Lucentis and Beovu) and a gene-therapy capability via AveXis/Zolgensma. Comparable as both a potential acquirer/partner and a benchmark for what commercial-scale ophthalmology infrastructure looks like.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Gyroscope Therapeutics social profiles

Digital presence

Gyroscope Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gyroscope Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Gyroscope Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gyroscope Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gyroscope Therapeutics

What does Gyroscope Therapeutics do?

Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye. Its lead investigational product, GT005, is being evaluated as a one-time gene therapy for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), an advanced form of the disease that causes progressive vision loss in adults over 50.

Is Gyroscope Therapeutics a public or private company?

Gyroscope Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gyroscope Therapeutics founded?

Gyroscope Therapeutics was founded in 2016. It employs 51 to 100 people.

Where is Gyroscope Therapeutics based?

Gyroscope Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.

Who are Gyroscope Therapeutics's main competitors?

Direct peers on record are Adverum Biotechnologies, REGENXBIO, MeiraGTx, Nanoscope Therapeutics, 4D Molecular Therapeutics, Apellis Pharmaceuticals and Iveric Bio (Astellas). Applied Genetic Technologies Corp (AGTC) is listed as an emerging player. Spark Therapeutics (Roche) is listed as a broad incumbent. Novartis is listed as an others.

Does Gyroscope Therapeutics have an API?

No public API is recorded for Gyroscope Therapeutics.

What industry is Gyroscope Therapeutics in?

Gyroscope Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Why Novartis (NVS) Is Buying Gyroscope For $1.5 BillionNovartis agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront, with up to $700 million in milestone payments. The deal targets Gyroscope's GT005 gene therapy for geographic atrophy, an unmet need in retinal disease, with Phase 1/2 trials ongoing.GlobeNewswireNovartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindnessNovartis agreed to acquire Gyroscope Therapeutics, adding its investigational gene therapy GT005 for geographic atrophy. The deal includes an upfront payment of $800 million and potential milestone payments up to $700 million. GT005 is in Phase 2 trials and has received FDA Fast Track designation.BenzingaBiotech Firms Gyroscope Therapeutics, Talaris Therapeutics Set IPO Terms - First Trust US Equity OpportunGyroscope Therapeutics Holdings plc, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, and U.S.-based Talaris Therapeutics, a Phase 3 biotech developing allogeneic hematopoietic stem cell transplantation methods, have both set IPO terms ahead of their planned listings on the Nasdaq Global Select Market. Gyroscope plans to offer 6.8 million ADSs at $20-$22 per share with a fully diluted market value of $633 million and an expected $142 million raise, while Talaris plans to offer 8.8 million shares at $16-$18 per share with a fully diluted market value of $736 million and an expected $150 million raise. Both companies are targeting listings later this week, with Gyroscope under the symbol "VISN" and Talaris under "TALS."AaoRPE Cell Transplants for Dry AMDLineage Cell Therapeutics reported positive safety and efficacy signals from a phase 1/2A clinical trial involving the transplantation of OpRegen, its stem cell-derived retinal pigment epithelial cells, into patients with advanced dry age-related macular degeneration. The study demonstrated that the treatment was well-tolerated and showed evidence of slowing disease progression, although initial cohorts experienced procedural complications such as macular fibrosis. Researchers are now testing a new delivery device, Orbit SDS by Gyroscope Therapeutics, to eliminate the need for vitrectomy and reduce these risks in ongoing trials.